Clinical Report: Identification of PGD, MAPK14, and KRAS as Biomarkers

Overview

This study identifies PGD, MAPK14, and KRAS as biomarkers for neonatal sepsis, supported by machine learning and immune infiltration assessments.

Background

Neonatal sepsis is a critical condition with high mortality rates, particularly in low- and middle-income countries. Current diagnostic methods are often slow, highlighting the need for reliable biomarkers.

Data Highlights

Key Findings

• PGD, MAPK14, and KRAS were identified as biomarkers through multiple machine learning models.
• All three biomarkers showed diagnostic performance with AUC values greater than 0.79.
• Immune infiltration analysis indicated increased neutrophils and Tregs, with decreased CD8+ T cells in sepsis patients.
• Molecular docking revealed dasatinib and gefitinib as binders to MAPK14 and KRAS.
• In vitro studies confirmed upregulation of PGD, MAPK14, and KRAS expression following LPS stimulation.
• Candidate drugs inhibited macrophage viability in experimental settings.

Clinical Implications

The identification of PGD, MAPK14, and KRAS as biomarkers could facilitate earlier diagnosis of neonatal sepsis, potentially improving clinical outcomes. The study also suggests that dasatinib and gefitinib may have therapeutic potential in managing sepsis-related inflammation.

Conclusion

PGD, MAPK14, and KRAS are identified as biomarkers for neonatal sepsis. Further investigation into their roles in sepsis pathogenesis is warranted.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Frontiers in Pediatrics — Serum LRG1 as a diagnostic marker of necrotizing enterocolitis in preterm infants
7. WHO recommendations for management of serious bacterial infections in infants aged 0–59 days
8. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children
9. International Consensus Criteria for Pediatric Sepsis and Septic Shock | Critical Care Medicine | JAMA | JAMA Network
10. Risk factors and clinical indicators: early-onset neonatal infection | Neonatal infection: antibiotics for prevention and treatment | Guidance | NICE
11. Presepsin as a diagnostic biomarker for sepsis across neonates, children, and adults: A meta-analysis - PubMed
12. Predictive gene expression signature diagnoses neonatal sepsis before clinical presentation - PMC
13. Management of neonates at risk of early onset sepsis: a probability-based approach and recent literature appraisal: Update of the Swiss national guideline of the Swiss Society of Neonatology and the Pediatric Infectious Disease Group Switzerland - PMC
14. The cell biology of ferroptosis | Nature Reviews Molecular Cell Biology
15. Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1) - PMC